Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liver Cancer: early-phase trial registry
30 of 81 indexed Liver Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #172 of 28,707 conditions by registered trial count.
81 US clinical trials · 30 currently recruiting · #172 of 28,707 conditions by registered trial count
Liver Cancer: 81 US clinical trials tracked, 30 recruiting.
Liver Cancer is the subject of 81 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition liver-cancer
OPEN 30 | RECR 37% | LATE 4 | EARLY 38 | RANK #172 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Bipolar I Disorder (37% recruiting · 27 trials)
Liver Cancer lists 30 open slots (37% of 81 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liver Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liver Cancer is recruiting below its size-band peers.
30 of 81 indexed trials (37%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Liver Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 8 of 81 trials (9.9%). 54 distinct sponsors appear on at least one study for this condition label.
-
Most Liver Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 79 trials that report a genuine target (sentinel values excluded). 50 of those (63.3%) plan for fewer than 100 participants.
-
Liver Cancer research is mostly interventional.
60 interventional and 21 observational studies make up this index (74.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
81 total, page 1 of 2
Biobank for Cholestatic Liver Diseases.
Mayo Clinic
NCT03445585
National Liver Cancer Screening Trial
University of Texas Southwestern Medical Center
NCT06084234
Collection of Blood From Patients With Cancer
National Cancer Institute (NCI)
NCT00034216
Multi-analyte Blood Test Clinical Trial
Helio Genomics
NCT05199259
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Cancer Institute (NCI)
NCT00451022
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Icahn School of Medicine at Mount Sinai
NCT05146297
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Stanford University
NCT00373347
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Cancer Institute (NCI)
NCT04145141
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
University of Colorado, Denver
NCT05517811
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Case Comprehensive Cancer Center
NCT07044362
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
4D-MRI for Precision Medicine
University of Virginia
NCT04657042
Jump: MR Simulation For Radiation Therapy Master Protocol
Brigham and Women's Hospital
NCT04545957
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
Duke University
NCT04933435
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
NCT07223307
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT06580002
Feasibility Study of CBCT for IGRT in Cancer Patients
Varian, a Siemens Healthineers Company
NCT06681233
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
M.D. Anderson Cancer Center
NCT07010315
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Montefiore Medical Center
NCT06899152
Y-90 Treatment Response Using Transarterial Radioembolization
Thomas Jefferson University
NCT07145801
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT07447050
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04715191
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
University of Kansas Medical Center
NCT05727787
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT07001592
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Allison O'Neill, MD
NCT04134559
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Eureka Therapeutics
NCT04634357
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Washington University School of Medicine
NCT06904365
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
NCT00582647
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
NCT05064553
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Bristol-Myers Squibb
NCT03383458
Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection
Memorial Sloan Kettering Cancer Center
NCT02523443
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
Memorial Sloan Kettering Cancer Center
NCT01494324
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
NCT05953337
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT05724563
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
NCT06384417
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
Memorial Sloan Kettering Cancer Center
NCT03143270
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Massachusetts General Hospital
NCT05128032
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
M.D. Anderson Cancer Center
NCT05743842
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience
NCT03552718
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04377932
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Baylor College of Medicine
NCT02932956
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Northwestern University
NCT00530010
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
A Retrospective Review of Malignant Liver Tumors
University of Oklahoma
NCT00728650
Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)
Northwestern University
NCT00866957
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
NCT01033240
Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy
Vanderbilt University
NCT00482586
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 22 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Liver Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liver Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liver Cancer page
81 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Liver Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Liver Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Cancer condition card totals 81 registered trials; most-linked intervention exatecan mesylate; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.